Stockscreener 앱 받기
8.24
2.60%
-0.22
시간 외 거래:
8.25
0.010
+0.12%
전일 마감가:
$8.46
열려 있는:
$8.42
하루 거래량:
2.97M
Relative Volume:
0.43
시가총액:
$1.91B
수익:
$510.17M
순이익/손실:
$146.93M
주가수익비율:
13.76
EPS:
0.599
순현금흐름:
$27.51M
1주 성능:
-0.36%
1개월 성능:
-24.75%
6개월 성능:
-52.04%
1년 성능:
-59.13%
1일 변동 폭
$8.18
$8.535
1주일 범위
$8.18
$8.78
52주 변동 폭
$7.2101
$22.37
Adma Biologics Inc Stock (ADMA) Company Profile
명칭
Adma Biologics Inc
전화
(201) 478-5552
주소
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
8.24 | 1.96B | 510.17M | 146.93M | 27.51M | 0.599 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Buy |
| 2026-03-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-07-19 | 재개 | Raymond James | Strong Buy |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2021-11-11 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-04 | 개시 | Jefferies | Buy |
| 2019-04-15 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-07 | 재개 | H.C. Wainwright | Buy |
| 2017-12-11 | 재확인 | Maxim Group | Buy |
| 2017-11-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | 업그레이드 | Maxim Group | Hold → Buy |
| 2016-08-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2016-07-25 | 재확인 | Maxim Group | Buy |
| 2015-05-13 | 재확인 | Maxim Group | Buy |
| 2014-12-08 | 개시 | Oppenheimer | Outperform |
| 2014-12-01 | 재확인 | Maxim Group | Buy |
모두보기
Adma Biologics Inc 주식(ADMA)의 최신 뉴스
$ADMA Shareholder Announcement: ADMA Biologics may have - GlobeNewswire
ADMA Biologics Inc (ADMA) Stock Analysis: Exploring a 103% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
ADMA Biologics declines 17% after lowering FY26 outlook, withdrawing long-term guidance - MSN
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - PR Newswire
IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are ... - Caledonian Record
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Lowey Dannenberg, P.C. is Investigating ADMA Biologics - GlobeNewswire
Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026? - Zacks Investment Research
B Group Increases Stake in ADMA Biologics by 750,000 Shares - Intellectia AI
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year - The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
A Look At ADMA Biologics (ADMA) Valuation After Securities Fraud Probes And Guidance Withdrawal - Sahm
ADMA Securities Investigation: ADMA Biologics 29% Stock - GlobeNewswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - FinancialContent
Why are shares of ADMA Biologics falling today? - MSN
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge? - TradingView
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inqu - GuruFocus
ADMA Biologics Inc (ADMA) Stock Price, Trades & News - GuruFocus
ADMA Fraud Notice: ADMA Biologics is being Investigated for - GlobeNewswire
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With 102.54% Potential Upside - DirectorsTalk Interviews
Understanding the Setup: (ADMA) and Scalable Risk - Stock Traders Daily
Thrivent Financial for Lutherans Cuts Position in ADMA Biologics Inc $ADMA - MarketBeat
How Channel Stuffing Probes and ASCENIV’s Pediatric Expansion Will Impact ADMA Biologics (ADMA) Investors - Yahoo Finance
ADMA Biologics (ADMA) price target decreased by 26.10% to 17.08 - MSN
ADMA Shareholder News: ADMA Biologics Investigated for Securities Fraud Over Alleged Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law - GlobeNewswire
ADMA Biologics IncCommon Stock (NQ: ADMA - FinancialContent
Here’s What Analysts Think About ADMA Biologics (ADMA) - Insider Monkey
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Adma biologics director Jerrold Grossman buys $100,125 in stock By Investing.com - Investing.com Nigeria
Adma biologics director Jerrold Grossman buys $100,125 in stock - Investing.com
ADMA Biologics (NASDAQ: ADMA) director adds 12,500 shares in open-market buy - Stock Titan
A Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations - Sahm
New Strong Sell Stocks for May 14th - The Globe and Mail
ADMA Investor News: If You Have Suffered Losses in ADMA - GlobeNewswire
ADMA Biologics Fair Value call delivered 50% gain despite volatility By Investing.com - Investing.com India
ADMA Biologics Fair Value call delivered 50% gain despite volatility - Investing.com UK
Adma Biologics director buys $100,125 of common stock - Investing.com UK
Adma Biologics director buys $100,125 of common stock By Investing.com - Investing.com Nigeria
Canaccord Cuts PT on ADMA Biologics Inc. (ADMA) But Remains a Buy on Shares - Insider Monkey
Adma Biologics Inc (ADMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):